(Anaveon) ANV600 is a novel PD-1 targeted IL-2Rβ/γ agonist that is combinable with therapeutic PD-1 inhibitors

Novel PD-1 targeted IL-2Rβ/γ agonist

November 1, 2023

Background

ANV600 combines a unique non-blocking PD-1 targeting approach with an IL-2Rβ/γ selective agonistic principle

The first arm of the bispecific antibody features an αIL-2/IL-2 fusion protein, which effectively prevents IL-2Rα from binding to the cytokine and therefore selectively activates IL-2Rβ/γ.The second arm consists of a high affinity αPD-1antibody to selectively deliver the IL-2Rβ/γ agonist to tumor antigen experienced PD-1+ T cells. The αPD-1arm binds to a unique epitope on PD-1 that enables combination of ANV600 with PD-1 checkpoint inhibitors.

Related products

Catalogue product

genO‑hPD‑1

The genO‑hPD‑1 mouse enables the in vivo efficacy assessment and profiling of compounds targeting the human immune checkpoint PD-1 in fully immunocompetent mice

Customized product

No items found.

Related posters

(Charles River) Novel in vivo preclinical humanized models for the evaluation of human specific immune checkpoint inhibitors.

hPD-1/hCTLA-4 mice to evaluate immune checkpoint inhibitors

(Charles River) Validation of humanized PD-1 knock-in mice as an emerging model to evaluate human specific PD-1 therapeutics

hPD-1 mice as a model to evaluate human specific PD-1 therapeutics

(Charles River) Enhanced anti-tumor lymphocyte function and frequencies measured by multichromatic flow cytometry in human CTLA-4 knock-in mice in a colorectal carcinoma model after treatment with ipilimumab

hCTLA-4 mice as a colorectal carcinoma model

(Kineta) A Fully Human anti-VISTA Antibody as a Promising Therapy Against Poorly Immunogenic Tumors

anti-hVISTA against poorly immunogenic tumors

(Arcus) AB598, a Therapeutic Anti-Human CD39 Antibody, Binds and Inhibits CD39 Enzymatic Activity In Vivo to Promote Anti-Tumor Immunity

Anti hCD39 to promote anti-tumor immunity

(Sensei) SNS-101, a monoclonal antibody that is highly selective for VISTA in the tumor microenvironment, demonstrates favorable pharmacokinetic and cytokine release characteristics and potentiates anti-PD-1 responsiveness

VISTA in the tumor microenvironment

(Curadev) Intravenous administration of the small molecule STING agonist CRD5500 elicits potent anti-tumor immune responses in cold tumors

hSTING & anti-tumor response in cold tumors

(AstraZeneca) AZD5863: a specific, potent, affinity-optimized Claudin 18.2 and CD3 binding T cell-engager that elicits low cytokine release and is capable of bystander killing

CD3 binding T-cell engagement

(VIB) A Cross-Species Map and Humanized Mouse Model of Fcγ Receptors and FcRn

Humanized Mouse Model of Fcγ Receptors

(Reaction Biology) Humanized PD-1 knock-in mice as a model system for combination therapies with human specific PD-1 therapeutics

hPD-1 to evaluate novel cancer therapies

(Anaveon) ANV600 is a potent, cis-signaling, IL-2Rβ/γ directed IL-2 which efficiently expands intratumoral stem-like CD8 T cells

PD-1 & strong tumor growth inhibition

(Maxivax) Sustained delivery of low-dose anti-CTLA-4 by genetically engineered encapsulated cells drives tumor response and prolongs survival in a colorectal cancer model

CTLA-4 & survival in a colorectal cancer model

(Sensei) Conditionally active CD28xVISTA bispecific antibodies induce myeloid-driven tumor-specific T-cell co-stimulation for improved cancer immunotherapy

CD28xVISTA bispecific antibodies in immunotherapy

(Bonum) A Novel Method for Generating Regulated Cytokine Therapeutics: Safety and Activity of a Conditionally Active cLAG3-IL2 Capable of Delivering IL-2 to LAG-3+ Cells While Remaining Inert on LAG-3- Cells

Safety and activity of a conditionally active cLAG3-IL2

(Cidara) Discovery of a multispecific CD73/PD-1 targeting Drug Fc-Conjugate (DFC), which improves tumor reduction compared to PD-1 monotherapy in a humanized mouse model

Multispecific CD73/PD-1 targeting

Novel FcγR humanized mouse models enabling efficacy and PK/PD of therapeutic antibodies

FcγR mouse models for efficacy and PK/PD

Novel TFRC humanized mouse model for drug delivery to the brain

Drug delivery to the brain (TFRC)

CD28 humanized mouse model for efficacy and safety assessment of CD28-targeting therapies

CD28-targeting therapies

Cell-depleting agents assessment in preclinical models

BRGSF-HIS & hFcγR to assess cell depletion

Translatable preclinical mouse models for assessment of T-cell engager-induced CRS

BRGSF-HIS & CD3ε in CRS

CD3 humanized mouse models as validated tools to assess immune-related adverse events of T-cell engagers

CD3 and BRGSF-HIS to assess IrAEs

Anti-VISTA agents profiling: complementarity of BRGSF-HIS and hVISTA Knock-in as preclinical models for immunotherapies

BRGSF-HIS & hVISTA for immunotherapies

Show all posters

Humanized targets